Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can group support help young LGBTQ+ brazilians stick to HIV meds?

NCT ID NCT06056037

Disease control Sponsor: Brown University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study is testing a group-based support program to help young sexual and gender minority people (ages 18-24) in Rio de Janeiro take their HIV medication consistently. The program includes four sessions that focus on building social support, self-confidence, and problem-solving skills. The goal is to see if the program is feasible and acceptable, and whether it improves medication adherence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention (group support sessions)
What this could lead to
If it works, this could point toward a low-cost, scalable way to improve HIV medication adherence among young sexual and gender minorities.
What could go wrong
This is a small pilot study (72 people) testing feasibility, not effectiveness. The results may not apply to other groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Oct 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 24 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * between 18 and 24 years of age * assigned male sex at birth * identify as a gay or bisexual man, or a transgender woman or another gender identity along the feminine spectrum * self-report living with HIV, and verified by medical chart review, * self-report currently taking or prescribed ART for \> 3 months * self-report missing 2 or more doses of ART medications in any given week in the past month OR not virally suppressed (i.e., \>40 copies/mL in past 3 months; via national outpatient data \[SISCEL\] or plasma viral load testing) * owns a cell phone or willing to use one as part of the study Exclusion Criteria: * unable to give informed consent due to cognitive limitation, severe mental/physical illness or intoxication * unable to read and/or write to an extent that would limit their ability to comprehend the informed consent * lived in the greater Rio de Janeiro area for \< 3 months or planning to move outside the area within the next year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence, medication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS Coitus HIV infectious disease Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence, medication HIV

Contacts and locations

Locations

  • Evandro Chagas National Institute of Infectious Diseases (INI) Oswaldo Cruz Foundation (FIOCRUZ)

    Rio de Janeiro, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.